Investigational drug · Phase 2
ABSK043
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive, HER2-Gastric/Gastroesophageal Junction Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
7
Any phase or sponsor naming "ABSK043"
First trial start
2024
Nov 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABSK043", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
- HER2-Gastric/Gastroesophageal Junction Cancer
- Urothelial Carcinoma
- Solid Tumors
- Non-Small Cell Lung Cancer With EGFR Mutation
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Bladder and urothelial cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ABSK043" as an intervention, largest first.
Abbisko Therapeutics Co, LtdIndustry
NCT06632262 · 202 participants (planned) · Start Nov 13, 2024 · Primary completion Nov 30, 2029
Drug: ABSK061 + ABSK043; ABSK061+ABSK043 in combination with CAPOX · For: HER2-Gastric/Gastroesophageal Junction Cancer; Urothelial Carcinoma; Non-Small Cell Lung Cancer and 1 more
Sites: Guiyang, China; Shijiazhuang, China; Harbin, China · 21 sites in all
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid TumorActive, not recruiting
Abbisko Therapeutics Co, LtdIndustry
NCT04964375 · 102 participants · Start Aug 31, 2021 · Primary completion Jul 30, 2027
Drug: ABSK043 oral capsule · For: Neoplasms
Sites: Brisbane, Australia; Frankston, Australia; Liverpool, Australia · 20 sites in all
Abbisko Therapeutics Co, LtdIndustry
NCT07164170 · 86 participants (planned) · Start Sep 22, 2025 · Primary completion Dec 30, 2028
Drug: ABSK043 in combination with Glecirasib · For: Non-Small Cell Lung Cancer
Sites: Hefei, China; Beijing, China; Fuzhou, China · 17 sites in all
- A Phase 2 Study of ABSK043 Combined With OsimertinibNot yet recruiting
Abbisko Therapeutics Co, LtdIndustry
NCT07710612 · 72 participants (planned) · Start Aug 31, 2026 · Primary completion Dec 31, 2029
Drug: ABSK043 in combination with Osimertinib · For: Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Sites: Guangzhou, China; Harbin, China; Wuhan, China · 7 sites in all
Abbisko Therapeutics Co, LtdIndustry
NCT06668103 · 54 participants (planned) · Start Nov 25, 2024 · Primary completion Dec 30, 2027
Drug: ABSK043 in combination with Firmonertinib · For: Non-Small Cell Lung Cancer With EGFR Mutation
Sites: Hefei, China; Harbin, China; Wuhan, China · 5 sites in all
RenJi HospitalAcademic, hospital or other
NCT06978933 · 42 participants (planned) · Start Apr 30, 2025 · Primary completion Dec 2026
Drug: ABSK-011 · For: HCC - Hepatocellular Carcinoma
Sites: Shanghai, China
University Health Network, TorontoAcademic, hospital or other
NCT07014137 · 20 participants (planned) · Start Sep 9, 2025 · Primary completion Mar 2, 2027
Drug: ABSK043 single agent · For: Sarcoma
Sites: Toronto, Canada
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.